Pharmafile Logo

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts provide insights on the trends, challenges and opportunities for biopharmaceutical companies, including why an interdisciplinary approach is needed to improve outcomes in oncology.

The theme of the 2023 American Society of Clinical Oncology congress, “Partnering With Patients: The Cornerstone of Cancer Care and Research,” highlights the growing cancer care gap preventing significant numbers of patients from benefiting from advancements in prevention, diagnosis, and treatment. These disparities are not due to a lack of innovation—novel approaches to testing and screening have driven an abundance of therapeutics that extend life and, in some cases, promise to cure disease.

However, many patients remain unable to access treatment due to social determinants such as proximity to treatment sites, affordability, lack of transport, age, language barriers, and income status.

As Joseph Mikhael, MD, professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute in Phoenix, Arizona, noted in a recent interview with Oncology Live, the top barriers driving healthcare disparities are:

  • Time to diagnosis
  • Time to therapy
  • Access to specialized centers
  • The four T’s—access to triplets, transplants, trials, and CAR-T
  • Physician bias

It will take tenacity and new ways of thinking to solve the deeply ingrained barriers preventing equitable treatment and care, and manufacturers will need to build greater connections across the community to collaborate with a wider range of stakeholders more deeply and earlier on to ensure the patient voice is central to the commercial strategy.

We hope you benefit from our oncology experts’ analysis of the global and North American trends and their recommendations for driving commercial success across a range of stakeholders within the oncology setting. By taking an interdisciplinary approach, and connecting advisory and executional capabilities, we hope to realize the potential of healthcare strategies and solutions that build connections that will result in improved outcomes for cancer patients.

Read on to learn about:

  • Driving uptake of biomarker testing among community oncologists
  • Integrating patient centricity across the commercialization path in multiple myeloma
  • The increasing influence of the Centers for Medicare and Medicaid Services on the commercialization of oncology products
  • Why applying a commercial lens to Phase 2 trials will drive launch success
  • Advice on commercializing CAR-T therapies—from driving equitable access to developing impactful and relevant marketing
  • A case study on determining endpoints in non-small-cell lung cancer

DOWNLOAD THE FULL ONCOLOGY EBOOK

This content was provided by Avalere Health

Company Details

 Latest Content from  Avalere Health 

Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient

As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.

Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities

As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies

Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.

Archetypes: Rethinking go-to-market expectations to drive commercial success

In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer

Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

The challenges of reimbursement and innovative pricing for cell and gene therapies

Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

Fishawack Health welcomes Mario Muredda as its new President of Marketing

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.